Biofrontera Inc. BFRI 深 滬
等待開盤 08-14 09:30:00 美东时间
0.959
+0.029
+3.12%
華盛通- 最 高0.9702
- 今 開0.91
- 成交量 3.23万股
- 最 低 0.91
- 昨 收 0.93
- 總市值 972.29万
- 52周最高 2.22
- 市盈率 靜 --
- 換手率 0.32%
- 52周最低 0.536
- 委 比 66.67%
- 總股本 1013.86万
- 歷史最高 292.60
- 量 比 0.64
- 振 幅 6.47%
- 歷史最低 0.536
- 每 手 1
- 風險率 0.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
A Look at Biofrontera's Upcoming Earnings Report
Biofrontera (NASDAQ:BFRI) is set to give its latest quarterly earnings report o...
08-13 01:02
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer
Biofrontera Inc. 宣布聘请George Jones为首席商务官，负责掌管公司的商业部门，包括销售、营销和市场准入。此次人事任命紧随公司与Biofrontera AG达成协议收购Ameluz®和RhodoLED®在美国市场的权益，这将显著提升公司的财务状况。Jones拥有超过25年的生物制药行业经验，其丰富的领导和团队建设经验将助力公司在光动力治疗领域进一步扩展。
08-11 20:25
Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025
Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in dermatological products, will report its second-quarter and first-half 2025 financial results on August 13, 2025. A conference call to discuss the results will be held on August 14 at 10:00am ET. The call can be accessed via phone or webcast.
08-04 18:00
Biofrontera Finalizes Acquisition of U.S. Ameluz Rights
Biofrontera ( ($BFRI) ) just unveiled an announcement. On June 30, 2025, Biofro...
07-01 21:15
Biofrontera Completes Strategic Restructuring Agreement
An announcement from Biofrontera ( ($DE:B8FK) ) is now available. Biofrontera A...
07-01 07:58
Biofrontera restructures relationship with Biofrontera AG, backed by $11M investment
Biofrontera (NASDAQ:BFRI) said on Monday that it has acquired all U.S. Rights to Ameluz and RhodoLED from its former parent company Biofrontera AG. An $11M investment led by Rosalind Advisors and AIG...
06-30 20:29
Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment
Biofrontera Inc. acquired U.S. rights to Ameluz® and RhodoLED® from Biofrontera AG, reducing royalties to 12% (or 15% above $65 million in revenue). The transaction, supported by an $11 million investment, aims to boost profitability and strengthen its U.S. dermatology market presence.
06-30 12:00
Biofrontera AG Extends Payment Deferral Amid Strategic Negotiations
The latest update is out from Biofrontera ( ($DE:B8FK) ). Biofrontera AG has an...
06-27 02:57
BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG
Biofrontera Inc. confirms negotiations with Biofrontera AG regarding potential company combination or adjustment of their license and supply agreement, which may involve transferring certain rights, obligations, and reducing transfer prices for products sold in the U.S. No definitive terms have been established yet.
06-11 19:00
